Association between systemic corticosteroids and outcomes of intensive care unit-acquired pneumonia


Autoria(s): Tavares Ranzani, Otavio; Ferrer, Miquel; Esperatti, Mariano; Giunta, Valeria; Li Bassi, Gianluigi; Ribeiro Carvalho, Carlos Roberto; Torres, Antoni
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

01/11/2013

01/11/2013

2012

Resumo

Objective: The use of corticosteroids is frequent in critically-ill patients. However, little information is available on their effects in patients with intensive care unit acquired pneumonia. We assessed patients' characteristics, microbial etiology, inflammatory response, and outcomes of previous corticosteroid use in patients with intensive care unit acquired pneumonia. Design: Prospective observational study. Setting: Intensive care units of a university teaching hospital. Patients: Three hundred sixteen patients with intensive care unit acquired pneumonia. Patients were divided according to previous systemic steroid use at onset of pneumonia. Interventions: None. Measurements and Main Results: Survival at 28 days was analyzed using Cox regression, with adjustment for the propensity for receiving steroid therapy. One hundred twenty-five (40%) patients were receiving steroids at onset of pneumonia. Despite similar baseline clinical severity, steroid treatment was associated with decreased 28-day survival (adjusted hazard ratio for propensity score and mortality predictors 2.503; 95% confidence interval 1.176-5.330; p = .017) and decreased systemic inflammatory response. In post hoc analyses, steroid treatment had an impact on survival in patients with nonventilator intensive care unit acquired pneumonia, those with lower baseline severity and organ dysfunction, and those without etiologic diagnosis or bacteremia. The cumulative dosage of corticosteroids had no significant effect on the risk of death, but bacterial burden upon diagnosis was higher in patients receiving steroid therapy. Conclusions: In critically-ill patients, systemic corticosteroids should be used very cautiously because this treatment is strongly associated with increased risk of death in patients with intensive care unit acquired pneumonia, particularly in the absence of established indications and in patients with lower baseline severity. Decreased inflammatory response may result in delayed clinical suspicion of intensive care unit acquired pneumonia and higher bacterial count. (Crit Care Med 2012; 40:2552-2561)

CibeRes [(CB06/06/0028)-ISCiii]

CibeRes

IDIBAPS

IDIBAPS

SEPAR-ALAT fellowship

SEPARALAT fellowship

[2009 SGR 911]

Identificador

CRITICAL CARE MEDICINE, PHILADELPHIA, v. 40, n. 9, supl. 2, Part 3, pp. 2552-2561, SEP, 2012

0090-3493

http://www.producao.usp.br/handle/BDPI/37191

10.1097/CCM.0b013e318259203d

http://dx.doi.org/10.1097/CCM.0b013e318259203d

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

PHILADELPHIA

Relação

CRITICAL CARE MEDICINE

Direitos

closedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #BACTERIAL COUNT #CORTICOSTEROIDS #INTENSIVE CARE UNIT-ACQUIRED PNEUMONIA #NOSOCOMIAL PNEUMONIA #VENTILATOR-ASSOCIATED PNEUMONIA #VENTILATOR-ASSOCIATED PNEUMONIA #NONSTEROIDAL ANTIINFLAMMATORY DRUGS #RESPIRATORY-DISTRESS-SYNDROME #CLINICAL-TRIALS #INFLAMMATORY RESPONSE #SEVERE SEPSIS #SEPTIC SHOCK #GLUCOCORTICOID TREATMENT #NOSOCOMIAL PNEUMONIA #ANTIBIOTIC-THERAPY #CRITICAL CARE MEDICINE
Tipo

article

original article

publishedVersion